Three oral drugs for low-grade serous ovarian and endometrial cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study is testing a combination of three oral medications (imlunestrant, abemaciclib, and selinexor) for women with certain types of ovarian or endometrial cancer that has returned or spread and has not responded to standard treatments. The goal is to see if this combination can shrink or slow the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have either low-grade serous ovarian, fallopian tube, or peritoneal cancer, OR endometrial cancer of a specific type (endometrioid or with an endometrioid component).
- Your tumor must have a normal (wild-type) TP53 gene.
- You must have at least one tumor that can be measured on a scan or exam.
- You must have received at least one type of hormone therapy before.
- You have not previously taken abemaciclib, selinexor, or similar drugs.
- You are 18 or older and are generally able to do daily activities (ECOG 0-2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether adding medicines to standard hormone therapy (letrozole) can control endometrial cancer that has come back, spread, or stopped responding to usual treatments. It also explores whether extra drugs (metformin or gedatolisib) improve results for certain patient groups.
This trial tests whether taking two oral medications (letrozole and abemaciclib) after standard chemotherapy can help keep advanced or recurrent endometrial cancer from coming back. It is for people whose cancer is estrogen receptor-positive and has certain favorable genetic features.
This trial tests a combination of two targeted pills (sapanisertib and serabelisib) with standard chemo (paclitaxel) for endometrial cancer that has come back or spread. A substudy also looks at combining these drugs with a special diet that lowers insulin levels.
This trial tests a combination of two oral targeted drugs (avutometinib and defactinib) plus letrozole (a hormone therapy) in people with low-grade serous ovarian cancer who have not yet had any systemic treatment.
This trial tests whether abemaciclib with letrozole can slow or shrink certain rare ovarian cancers that have estrogen receptors. It may help people whose cancer has come back and can be measured on scans, with extra required tissue and blood tests.
This trial studies a combination of two oral drugs, elacestrant and everolimus, for advanced or recurrent endometrial cancer that is hormone receptor positive. The goal is to see if this combination can help shrink or slow the cancer.
Hear when a new Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.